- Home
- RAND vs MDXH Comparison
RAND vs MDXH Comparison
Compare RAND & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- MDXH
- Stock Information
- Founded
- RAND 1969
- MDXH 2003
- Country
- RAND United States
- MDXH Belgium
- Employees
- RAND N/A
- MDXH N/A
- Industry
- RAND Finance: Consumer Services
- MDXH
- Sector
- RAND Finance
- MDXH
- Exchange
- RAND Nasdaq
- MDXH Nasdaq
- Market Cap
- RAND 80.9M
- MDXH 73.3M
- IPO Year
- RAND N/A
- MDXH 2021
- Fundamental
- Price
- RAND $18.77
- MDXH $1.45
- Analyst Decision
- RAND
- MDXH Buy
- Analyst Count
- RAND 0
- MDXH 1
- Target Price
- RAND N/A
- MDXH $6.00
- AVG Volume (30 Days)
- RAND 17.9K
- MDXH 99.9K
- Earning Date
- RAND 03-10-2025
- MDXH 04-30-2025
- Dividend Yield
- RAND 27.01%
- MDXH N/A
- EPS Growth
- RAND 35.26
- MDXH N/A
- EPS
- RAND 3.42
- MDXH N/A
- Revenue
- RAND $8,559,285.00
- MDXH $90,049,000.00
- Revenue This Year
- RAND N/A
- MDXH $23.38
- Revenue Next Year
- RAND N/A
- MDXH $16.84
- P/E Ratio
- RAND $5.60
- MDXH N/A
- Revenue Growth
- RAND 16.64
- MDXH 28.29
- 52 Week Low
- RAND $13.69
- MDXH $1.35
- 52 Week High
- RAND $31.89
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- RAND 38.99
- MDXH 34.12
- Support Level
- RAND $18.62
- MDXH $1.55
- Resistance Level
- RAND $26.00
- MDXH $1.66
- Average True Range (ATR)
- RAND 1.40
- MDXH 0.08
- MACD
- RAND -0.18
- MDXH 0.00
- Stochastic Oscillator
- RAND 6.10
- MDXH 11.90
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.